Severe paraneoplastic gastroparesis associated with anti-Hu antibodies preceding the manifestation of small-cell lung cancer

Zeitschrift fur Gastroenterologie

Volumn 46, Issue 3, 2008, Pages 274-278

  Nguyen tat, Marc ^a,b   Pohl, J ^a   Gunter E ^a   Wanner, H ^a   Plum, N ^a   Pech, O ^a   Ell, C ^a  

^a HSK Wiesbaden ^*  (Germany)

^b Innere Medizin II   (Germany)

Author keywords

Anti Hu antibodies; Enteric ganglionitis; Paraneoplastic gastroparesis

Indexed keywords

CARBOPLATIN; ERYTHROMYCIN; ETOPOSIDE; HU ANTIBODY; METOCLOPRAMIDE; PYRIDOSTIGMINE;

ABDOMINAL RADIOGRAPHY; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; GASTROSCOPY; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; INTESTINE PSEUDOOBSTRUCTION; JEJUNUM; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; PARANEOPLASTIC SYNDROME; STOMACH DISTENSION; STOMACH MOTILITY; STOMACH PARESIS; TUBE FEEDING; VOMITING; WEIGHT REDUCTION;

AGED; AUTOANTIBODIES; CARCINOMA, SMALL CELL; GASTROPARESIS; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; LUNG NEOPLASMS; MALE; PARANEOPLASTIC SYNDROMES;

EID: 41949111634     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963429     Document Type: Article

References (14)

1. Soykan I, Sivri B, Sarosiek I et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998; 43: 2398-2404
2. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349: 1543-1554
3. De Giorgio R, Guerrini S, Barbara G et al. Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004; 126: 1872-1883
4. Park MI, Camilleri M. Gastroparesis: clinical update. Am J Gastroenterol 2006; 101: 1129-1139
5. China JS, Schuffler MD. Paraneoplastic visceral neuropathy as a cause of severe gastrointestinal motor dysfunction. Gastroenterology 1988; 95: 1279-1286
6. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and onocological profiles of patients seropositive for type 1 anti-neuronal autoantibodies. Neurology 1998; 50: 652-657
7. Graus F, Keime-Guibert F, Rene R et al. Anti-Hu associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124: 1138-1148
8. Graus F, Delattre JY, Antoine JC et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-1140
9. Lee HR, Lennon VA, Camilleri M et al. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterology 2001; 96: 373-379
10. Dalmau J, Graus F, Rosenblum MK et al. Anti-Hu associated paraneoplastic encephalomyelitis/sensory neuropathy: a clinical study of 71 patients. Medicine 1992; 71: 59-72
11. Graus F, Dalmou J, Rene R et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997; 15: 2866-2872
12. De Giorgio R, Bovara M, Barbara G et al. Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. Gastroenterology 2003; 125: 70-79
13. Voltz R. Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes. J Neurol 2006; 253 (Suppl 5): V/33-V/38
14. Keime-Guibert F, Graus F, Fleury A et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68: 479-482